文献リスト

1）Cho YK, Kim JK, Kim WT, et al. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology. 2010; 51(4): 1284-90

2）Ikeda K, Kobayashi M, Kawamura Y, et al. Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model. Liver Int. 2011; 31(5): 692-9

3）Peng ZW, Lin XJ, Zhang YJ, et al. Radiofrequency ablation versus hepatic resection for the treatment of hepatocellular carcinomas 2 cm or smaller: a retrospective comparative study. Radiology. 2012; 262(3): 1022-33

4）Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg. 2010; 252(6): 903-12

5）Kawamura Y, Ikeda K, Seko Y, et al. Hetero-geneous type 4 enhancement of hepatocellular carcinoma on dynamic CT is associated with tumor recurrence after radiofrequency ablation. AJR Am J Roentgenol. 2011; 197(4): W665-73

6）Peng ZW, Liang HH, Chen MS, et al. Conformal radiofrequency ablation of hepatocellular carcinoma with a multi-pin bipolar system. J Surg Oncol. 2011; 103(1): 69-74

7）Baldwin K, Katz SC, Rubin A, et al. Bipolar radiofrequency ablation of liver tumors: Technical experience and interval follow-up in 22 patients with 33 ablations. J Surg Oncol. 2012 May 4. doi: 10.1002/jso.23147. [Epub ahead of print]

8）Lencioni R, Crocetti L, Cioni D, et al. Single-session percutaneous ethanol ablation of early-stage hepatocellular carcinoma with a multipronged injection needle: results of a pilot clinical study. J Vasc Interv Radiol. 2010; 21(10): 1533-8

9）Giorgio A, Di Sarno A, De Stefano G, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma compared to percutaneous ethanol injection in treatment of cirrhotic patients: an Italian randomized controlled trial. Anticancer Res. 2011; 31(6): 2291-5

10）Kawamura R, Seki T, Umehara, et al. Combined treatment of large hepatocellular carcinoma with transcatheter arterial chemoembolization and percutaneous ethanol injection with a multipronged needle: experimental and clinical investigation. Cardiovasc Intervent Radiol. 2012; 35(2): 325-33

11）Gao F, Gu YK, Fan WJ, Zhang L, et al. State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen Evaluation of transarterial chemoembolization combined with percutaneous ethanol ablation for large hepatocellular carcinoma. World J Gastroenterol. 2011; 17(26): 3145-50

12）Livraghi T, Meloni F, Solbiati L, For the Collaborative Italian Group using AMICA system. Complications of Microwave Ablation for Liver Tumors: Results of a Multicenter Study. Cardiovasc Intervent Radiol. 2011 Aug 11. [Epub ahead of print]

13）Takami Y, Ryu T, Wada Y, et al. Evaluation of intraoperative microwave coagulo-necrotic therapy (MCN) for hepatocellular carcinoma: a single center experience of 719 consecutive cases. J Hepatobiliary Pancreat Sci. 2012 Jun 19. [Epub ahead of print]

14）Simo KA, Sereika SE, Newton KN, et al. Laparoscopic-assisted microwave ablation for hepatocellular carcinoma: safety and efficacy in comparison with radiofrequency ablation. J Surg Oncol. 2011; 104(7): 822-9

15）Lee KF, Hui JW, Cheung YS, et al. Surgical ablation of hepatocellular carcinoma with 2.45-GHz microwave: a critical appraisal of treatment outcomes. Hong Kong Med J. 2012; 18(2): 85-91

16）Jin C, Zhu H, Wang Z, et al. High-intensity focused ultrasound combined with transarterial chemoembolization for unresectable hepato-cellular carcinoma: long-term follow-up and clinical analysis. Eur J Radiol. 2011; 80(3): 662-9

17）Narayanan G, Froud T, Lo K, et al. Pain Analysis in Patients with Hepatocellular Carcinoma: Irreversible Electroporation versus Radio-frequency Ablation-Initial Observations. Cardio-vasc Intervent Radiol. 2012 Jun 30. [Epub ahead of print]

18）Louis C, Dewas S, Mirabel X, et al. Stereotactic radiotherapy of hepatocellular carcinoma: preliminary results. Technol Cancer Res Treat. 2010; 9(5): 479-87

19）Facciuto ME, Singh MK, Rochon C, et al. Stereotactic body radiation therapy in hepato-cellular carcinoma and cirrhosis: evaluation of radiological and pathological response. J Surg Oncol. 2012; 105(7): 692-8

20）Oh D, Lim do H, Park HC, et al. Early three-dimensional conformal radiotherapy for patients with unresectable hepatocellular carcinoma after incomplete transcatheter arterial chemo-embolization: a prospective evaluation of efficacy and toxicity. Am J Clin Oncol. 2010; 33(4): 370-5

21）Shin YJ, Kim MS, Yoo SY, et al. Pilot study of stereotactic body radiotherapy for huge hepatocellular carcinoma unsuitable for other therapies. Tumori. 2010; 96(1): 65-70

22）Koo JE, Kim JH, Lim YS, et al. Combination of transarterial chemoembolization and three-dimensional conformal radiotherapy for hepatocellular carcinoma with inferior vena cava tumor thrombus. Int J Radiat Oncol Biol Phys. 2010; 78(1): 180-7

23）Combs SE, Habermehl D, Ganten T, et al. Phase I study evaluating the treatment of patients with hepatocellular carcinoma (HCC) with carbon ion radiotherapy: the PROMETHEUS-01 trial. BMC Cancer. 2011; 11: 67

24）Kim JW, Seong J, Yun M, et al. Usefulness of positron emission tomography with fluorine-18-fluorodeoxyglucose in predicting treatment response in unresectable hepatocellular carci-noma patients treated with external beam radio-therapy. Int J Radiat Oncol Biol Phys. 2012; 82(3): 1172-8

25）Lammer J, Malagari K, Vogl T, et al; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010; 33(1): 41-52

26）Nawawi O, Hazman M, Abdullah B, et al. Transarterial embolisation of hepatocellular carcinoma with doxorubicin-eluting beads: single centre early experience. Biomed Imaging Interv J. 2010; 6(1): e7

27）Reyes DK, Vossen JA, Kamel IR, et al. Geschwind JF. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J. 2009; 15(6): 526-32

28）Dhanasekaran R, Kooby DA, Staley CA, et al. Comparison of conventional transarterial chemo-embolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol. 2010; 101(6): 476-80

29）Scartozzi M, Baroni GS, Faloppi L, et al. Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. J Exp Clin Cancer Res. 2010; 29: 164

30）Joh DH, Kim JD, Kim YN, et al. A case of hepatocellular carcinoma in the caudate lobe successfully treated by transcatheter arterial chemoembolization using drug-eluting beads. Korean J Hepatol. 2010; 16(4): 405-9

31）Wiggermann P, Sieron D, Brosche C, et al. Stroszczynski C. Transarterial Chemoembo-lization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE). Med Sci Monit. 2011; 17(4): CR189-95

32）Song MJ, Park CH, Kim JD, et al. Drug-eluting bead loaded with doxorubicin versus conven-tional Lipiodol-based transarterial chemo-embolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients. Eur J Gastroenterol Hepatol. 2011; 23(6): 521-7

33）Sacco R, Bargellini I, Bertini M, et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepato-cellular carcinoma. J Vasc Interv Radiol. 2011; 22(11): 1545-52

34）Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design. J Hepatol. 2012; 56(6): 1330-5. Epub 2012 Feb 5

35）Xie F, Zang J, Guo X, et al. Comparison of transcatheter arterial chemoembolization and microsphere embolization for treatment of unresectable hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2012; 138(3): 455-62

36）Pomoni M, Malagari K, Moschouris H, et al. Post embolization syndrome in doxorubicin eluting chemoembolization with DC bead. Hepato-gastroenterology. 2012; 59(115): 820-5

37）Guiu B, Deschamps F, Aho S, et al. Liver/biliary injuries following chemoembolisation of endo-crine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol. 2012; 56(3): 609-17

38）Vogl TJ, Lammer J, Lencioni R, et al. Liver, gastrointestinal, and cardiac toxicity in inter-mediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: re-sults from the PRECISION V randomized trial. AJR Am J Roentgenol. 2011; 197(4): W562-70

39）Malagari K, Pomoni M, Spyridopoulos TN, et al. Safety profile of sequential transcatheter chemo-embolization with DC Bead™: results of 237 hepatocellular carcinoma (HCC) patients. Car-diovasc Intervent Radiol. 2011; 34(4): 774-85

40）Aladdin M, Ilyas M. Chemoembolization of hepatocellular carcinoma with drug-eluting beads complicated by interstitial pneumonitis. Semin Intervent Radiol. 2011; 28(2): 218-21

41）Khan I, Vasudevan V, Nallagatla S, et al. Acute lung injury following transcatheter hepatic arterial chemoembolization of doxorubicin-loaded LC beads in a patient with hepatocellular carcinoma. Lung India. 2012; 29(2): 169-72

42）Lesevic V, Marzano E, Greget M, et al. Severe complication after a doxorubicin-eluting-bead embolization: surgical management and pathological findings. Cardiovasc Intervent Radiol. 2011; 34 Suppl 2: S186-9

43）Poggi G, Quaretti P, Montagna B, et al. Acute thrombocytopenia: an unusual complication occurring after drug-eluting microspheres transcatheter hepatic chemoembolization. Cardiovasc Intervent Radiol. 2011; 34 Suppl 2: S190-4

44）Namur J, Citron SJ, Sellers MT, et al. Embolization of hepatocellular carcinoma with drug-eluting beads: doxorubicin tissue concentration and distribution in patient liver explants. J Hepatol. 2011; 55(6): 1332-8

45）Uller W, Wiggermann P, Gossmann H, et al. Evaluation of the microcirculation of hepato-cellular carcinomas using contrast-enhanced ultrasound with intraarterial and intravenous contrast application during transarterial chemo-embolization with drug-eluting beads (DEB-TACE): preliminary data. Clin Hemorheol Microcirc. 2011; 49(1-4): 55-66

46）Recchia F, Passalacqua G, Filauri P, et al. Chemoembolization of unresectable hepato-cellular carcinoma: Decreased toxicity with slow-release doxorubicin‑eluting beads compared with lipiodol. Oncol Rep. 2012; 27(5): 1377-83

47）Golowa YS, Cynamon J, Reinus JF, et al. Value of noncontrast CT immediately after transarterial chemoembolization of hepatocellular carcinoma with drug-eluting beads. J Vasc Interv Radiol. 2012; 23(8): 1031-5

48）Seki A, Hori S, Kobashi K, et al. Transcatheter arterial chemoembolization with epirubicin-loaded superabsorbent polymer microspheres for 135 hepatocellular carcinoma patients: single-center experience. Cardiovasc Intervent Radiol. 2011; 34(3): 557-65

49）van Malenstein H, Maleux G, Vandecaveye V, et al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkol-ogie. 2011; 34(7): 368-76

50）Bonomo G, Pedicini V, Monfardini L, et al. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol. 2010; 33(3): 552-9

51）Sottani C, Poggi G, Quaretti P, et al. Serum pharmacokinetics in patients treated with transarterial chemoembolization (TACE) using two types of epirubicin-loaded microspheres. Anticancer Res. 2012; 32(5): 1769-74

52）Malagari K, Pomoni M, Kelekis A, et al. Prospective randomized comparison of chemo-embolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2010; 33(3): 541-51

53）Hanada M, Takasu H, Kitaura M. Acquired resistance to miriplatin in rat hepatoma AH109A/MP10 is associated with increased Bcl-2 expression, leading to defects in inducing apoptosis. Oncol Rep. 2010; 24(4): 1011-8

54）Imai N, Ikeda K, Seko Y, et al. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepato-cellular carcinoma. Oncology. 2011; 80(3-4): 188-94

55）Okabe K, Beppu T, Haraoka K, et al. Safety and short-term therapeutic effects of miriplatin-lipiodol suspension in transarterial chemo-embolization (TACE) for hepatocellular carcinoma. Anticancer Res. 2011; 31(9): 2983-8

56）Imai Y, Chikayama T, Nakazawa M, et al. Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Gastroenterol. 2011 Oct 6. [Epub ahead of print]

57）Imai N, Ikeda K, Kawamura Y, et al. Transcatheter arterial chemotherapy using miriplatin-lipiodol suspension with or without embolization for unresectable hepatocellular carcinoma. Jpn J Clin Oncol. 2012; 42(3): 175-82

58）Yodono H, Matsuo K, Shinohara A. A retrospective comparative study of epirubicin-lipiodol emulsion and cisplatin-lipiodol suspension for use with transcatheter arterial chemoembolization for treatment of hepato-cellular carcinoma. Anticancer Drugs. 2011; 22(3): 277-82

59）Sahara S, Kawai N, Sato M, et al. Prospective comparison of transcatheter arterial chemo-embolization with Lipiodol-epirubicin and Lipiodol-cisplatin for treatment of recurrent hepatocellular carcinoma. Jpn J Radiol. 2010; 28(5): 362-8

60）Boulin M, Ciboulet A, Guiu B, et al. Randomised controlled trial of lipiodol transarterial chemo-embolisation with or without amiodarone for unresectable hepatocellular carcinoma. Dig Liver Dis. 2011; 43(11): 905-11

61）Morse MA, Hanks BA, Suhocki P, et al. Improved time to progression for transarterial chemo-embolization compared with transarterial embo-lization for patients with unresectable hepato-cellular carcinoma. Clin Colorectal Cancer. 2012 Jan 24. [Epub ahead of print]

62）Kawamura Y, Ikeda K, Hirakawa M, et al. Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin. Hepatol Res. 2009; 39(4): 346-54

63）Maeda N, Osuga K, Higashihara H, et al. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion. Cardiovasc Intervent Radiol. 2012; 35(1): 82-9

64）Iwasa S, Ikeda M, Okusaka T, et al. Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to trans-catheter arterial chemoembolization. Jpn J Clin Oncol. 2011; 41(6): 770-5

65）Seki A, Hori S. Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2012; 35(3): 555-62

66）Zhou B, Shan H, Zhu KS, et al. Chemo-embolization with lobaplatin mixed with iodized oil for unresectable recurrent hepatocellular carcinoma after orthotopic liver transplantation. J Vasc Interv Radiol. 2010; 21(3): 333-8

67）Yamasaki T, Hamabe S, Saeki I, et al. A novel transcatheter arterial infusion chemotherapy using iodized oil and degradable starch microspheres for hepatocellular carcinoma: a prospective randomized trial. J Gastroenterol. 2011; 46(3): 359-66

68）Choi YH, Chung JW, Son KR, et al. Novel intraarterial therapy for liver cancer using ethylbromopyruvate dissolved in an iodized oil. Acad Radiol. 2011; 18(4): 471-8

69）Hilgard P, Hamami M, Fouly AE, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010; 52(5): 1741-9

70）Lance C, McLennan G, Obuchowski N, et al. Comparative analysis of the safety and efficacy of transcatheter arterial chemoembolization and yttrium-90 radioembolization in patients with unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2011; 22(12): 1697-705

71）Sangro B, Carpanese L, Cianni R, European Network on Radioembolization with Yttrium-90 Resin Microspheres (ENRY). Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology. 2011; 54(3): 868-78

72）Kooby DA, Egnatashvili V, Srinivasan S, et al. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol. 2010; 21(2): 224-30

73）Garin E, Rolland Y, Boucher E, et al. First experience of hepatic radioembolization using microspheres labelled with yttrium-90 (TheraSphere): practical aspects concerning its implementation. Eur J Nucl Med Mol Imaging. 2010; 37(3): 453-61

74）Iñarrairaegui M, Thurston KG, Bilbao JI, et al. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2010; 21(8): 1205-12

75）Tsai AL, Burke CT, Kennedy AS, et al. Use of yttrium-90 microspheres in patients with advanced hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2010; 21(9): 1377-84

76）Chuan-Xing L, Xu H, Bao-Shan H, et al. Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus: chemoembolization and stent combined with iodine-125 seed. Cancer Biol Ther. 2011; 12(10): 865-71

77）Hoffmann RT, Paprottka PM, Schon A, et al. Transarterial hepatic yttrium-90 radio-embolization in patients with unresectable intra-hepatic cholangiocarcinoma: factors associated with prolonged survival. Cardiovasc Intervent Radiol. 2012; 35(1): 105-16

78）Gaba RC, Riaz A, Lewandowski RJ, et al. Safety of yttrium-90 microsphere radioembolization in patients with biliary obstruction. J Vasc Interv Radiol. 2010; 21(8): 1213-8

79）Wu L, Yang YF, Ge NJ, et al. Hepatic arterial iodine-131-labeled metuximab injection com-bined with chemoembolization for unresectable hepatocellular carcinoma: interim safety and survival data from 110 patients. Cancer Biother Radiopharm. 2010; 25(6): 657-63

80）Burgmans MC, Irani FG, Chan WY, et al. Radioembolization after portal vein embolization in a patient with multifocal hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2012 Apr 14. [Epub ahead of print]

81）Liu YS, Chuang MT, Tsai YS, et al. Nitroglycerine use in transcatheter arterial (chemo)embolization in patients with hepatocellular carcinoma and dual-energy CT assessment of Lipiodol retention. Eur Radiol. 2012 May 24. [Epub ahead of print]

82）Peng PD, Hyder O, Bloomston M, et al. Sequential intra-arterial therapy and portal vein embolization is feasible and safe in patients with advanced hepatic malignancies. HPB (Oxford). 2012; 14(8): 523-31

83）Chung GE, Lee JH, Kim HY, et al. Transarterial chemoembolization can be safely performed in patients with hepatocellular carcinoma invading the main portal vein and may improve the overall survival. Radiology. 2011; 258(2): 627-34

84）Yoo DJ, Kim KM, Jin YJ, et al. Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients? J Gastroenterol Hepatol. 2011; 26(1): 145-54

85）Yamanaka K, Hatano E, Kitamura K, et al. Early evaluation of transcatheter arterial chemo-embolization-refractory hepatocellular carci-noma. J Gastroenterol. 2012; 47(3): 343-6

86）Katamura Y, Aikata H, Kimura Y, et al. Intra-arterial 5-fluorouracil/interferon combination therapy for hepatocellular carcinoma with portal vein tumor thrombosis and extrahepatic metastases. J Gastroenterol Hepatol. 2010; 25(6): 1117-22

87）Kasai K, Ushio A, Kasai Y, et al. Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma. Int J Clin Oncol. 2011; 16(3): 221-9

88）Nagano H, Wada H, Kobayashi S, et al. Long-term outcome of combined interferon-α and 5-fluorouracil treatment for advanced hepatocellular carcinoma with major portal vein thrombosis. Oncology. 2011; 80(1-2): 63-9

89）Monden M, Sakon M, Sakata Y, et al. FAIT Research Group. 5-fluorouracil arterial infu-sion + interferon therapy for highly advanced hepatocellular carcinoma: A multicenter, randomized, phase II study. Hepatol Res. 2012; 42(2): 150-65

90）Kasai K, Ushio A, Kasai Y, et al. Therapeutic efficacy of combination therapy with intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma with portal venous invasion. Cancer. 2012; 118(13): 3302-10

91）Kirikoshi H, Yoneda M, Mawatari H, et al. Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? World J Gastroenterol. 2012; 18(16): 1933-9

92）Kim HY, Kim JD, Bae SH, et al. Korean Liver Cancer Study Group. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepato-cellular carcinoma. Korean J Hepatol. 2010; 16(4): 355-61

93）Yamashita T, Arai K, Sunagozaka H, et al. Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology. 2011; 81(5-6): 281-90

94）Chuma M, Taguchi H, Yamamoto Y, et al. Efficacy of therapy for advanced hepatocellular carcinoma: intra-arterial 5-fluorouracil and subcutaneous interferon with image-guided radiation. J Gastroenterol Hepatol. 2011; 26(7): 1123-32

95）Murakami E, Aikata H, Miyaki D, et al. Hepatic arterial infusion chemotherapy using 5-fluorouracil and systemic interferon-α for advanced hepatocellular carcinoma in combination with or without three-dimensional conformal radiotherapy to venous tumor thrombosis in hepatic vein or inferior vena cava. Hepatol Res. 2012; 42(5): 442-53

96）Lee S, Yoon SH, Park JY, et al. Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study. Invest New Drugs. 2012; 30(3): 1150-7

97）Jeong SW, Jang JY, Lee JE, et al. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepato-cellular carcinoma. Asia Pac J Clin Oncol. 2012; 8(2): 164-71

98）Sanoff HK, Bernard S, Goldberg RM. Phase II study of capecitabine, oxaliplatin, and cetuximab for advanced hepatocellular carcinoma. Gastrointest Cancer Res. 2011; 4(3): 78-83

99）Coriat R, Mir O, Cessot A, et al. Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: experience in a cohort of advanced hepatocellular carcinoma patients. Invest New Drugs. 2012; 30(1): 376-81

100）Uchino K, Obi S, Tateishi R, et al. Systemic combination therapy of intravenous continuous 5-fluorouracil and subcutaneous pegylated interferon alfa-2a for advanced hepatocellular carcinoma. J Gastroenterol. 2012 Mar 22. [Epub ahead of print]

101）Hirano G, Sakurai K, Sohda T, et al. Systemic chemotherapy using carboplatin and 5-fluorouracil for extrahepatic metastasis of hepatocellular carcinoma. Hepatogastro-enterology. 2012; 59(119)

102）Kim HY, Park JW, Nam BH, et al. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments. J Gastroenterol Hepatol. 2011; 26(11): 1612-8

103）Pinter M, Hucke F, Graziadei I, et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology. 2012; 263(2): 590-9

104）Otsuka T, Eguchi Y, Kawazoe S, et al. the Saga Liver Cancer Study Group. Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res. 2012 Feb 29. doi: 10.1111/j.1872-034X. 2012. 00991.x. [Epub ahead of print]

105）Estfan B, Byrne M, Kim R. Sorafenib in advanced hepatocellular carcinoma: Hypertension as a potential surrogate marker for efficacy. Am J Clin Oncol. 2012 Apr 27. [Epub ahead of print]

106）Pinter M, Sieghart W, Hucke F, et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther. 2011; 34(8): 949-59

107）Lee JH, Park JY, Kim do Y, et al. Prognostic value of 18F-FDG PET for hepatocellular carci-noma patients treated with sorafenib. Liver Int. 2011; 31(8): 1144-9

108）Tsukui Y, Mochizuki H, Hoshino Y, et al. Factors Contributing to the overall survival in patients with hepatocellular carcinoma treated by sorafenib. Hepatogastroenterology. 2012 Apr 12;59(120). doi: 10.5754/hge12059. [Epub ahead of print]

109）Baek KK, Kim JH, Uhm JE, et al. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models. Oncology. 2011; 80(3-4): 167-74

110）Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial. J Hepatol. 2012 Jun 19. [Epub ahead of print]

111）Llovet JM, Peña CE, Lathia CD, et al. SHARP Investigators Study Group. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012; 18(8): 2290-300

112）Cheng AL, Guan Z, Chen Z, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial. Eur J Cancer. 2012; 48(10): 1452-65

113）Miyahara K, Nouso K, Tomoda T, et al. Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma. J Gastroenterol Hepatol. 2011; 26(11): 1604-11

114）Iavarone M, Cabibbo G, Piscaglia F, et al. SOFIA (SOraFenib Italian Assessment) study group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology. 2011; 54(6): 2055-63

115）Sacco R, Bargellini I, Ginanni B, et al. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice? Expert Rev Anticancer Ther. 2012; 12(7): 869-75

116）Morimoto M, Numata K, Kondo M, et al. Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib. Hepatol Res. 2011; 41(4): 296-302

117）Moschouris H, Malagari K, Gkoutzios P, et al. Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography. Med Ultrason. 2012; 14(2): 87-94

118）Schraml C, Schwenzer NF, Martirosian P, et al. Diffusion-weighted MRI of advanced hepato-cellular carcinoma during sorafenib treatment: initial results. AJR Am J Roentgenol. 2009; 193(4): W301-7

119）Spira D, Fenchel M, Lauer UM, et al. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib. Acad Radiol. 2011; 18(1): 89-96

120）Edeline J, Boucher E, Rolland Y, et al. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma. Cancer. 2012; 118(1): 147-56

121）Shao YY, Lin ZZ, Hsu C, et al. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer. 2010; 116(19): 4590-6

122）Yau T, Yao TJ, Chan P, et al. The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist. 2011; 16(9): 1270-9

123）Kuzuya T, Asahina Y, Tsuchiya K, et al. Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology. 2011; 81(3-4): 251-8

124）Nakazawa T, Hidaka H, Shibuya A, et al. Rapid regression of advanced hepatocellular carcinoma associated with elevation of des-gamma-carboxy prothrombin after short-term treatment with sorafenib – a report of two cases. Case Rep Oncol. 2010; 3(2): 298-303

125）Ueshima K, Kudo M, Takita M, et al. Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma. Dig Dis. 2011; 29(3): 321-5

126）Zugazagoitia J, Manzano A, Sastre J, et al. Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function. Clin Transl Oncol. 2012 Aug 9. [Epub ahead of print]

127）Abou-Alfa GK, Amadori D, Santoro A, et al. Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis. Gastrointest Cancer Res. 2011; 4(2): 40-4

128）Raoul JL, Bruix J, Greten TF, et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol. 2012; 56(5): 1080-8

129）Chiu J, Tang YF, Yao TJ, et al. The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: A retrospective analysis of efficacy, safety, and survival benefits. Cancer. 2012 Apr 19. doi: 10.1002/cncr.27543. [Epub ahead of print]

130）Lee JH, Chung YH, Kim JA, et al. Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer. 2012 Jun 26. doi: 10.1002/cncr.27705. [Epub ahead of print]

131）Bozkurt Duman B, Kara B, Oguz Kara I, et al. Hand-foot syndrome due to sorafenib in hepatocellular carcinoma treated with vitamin E without dose modification; a preliminary clinical study. J BUON. 2011; 16(4): 759-64

132）Horiuchi-Yamamoto Y, Gemma A, Taniguchi H, et al. Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan. Int J Clin Oncol. 2012 Jun 30. [Epub ahead of print]

133）Valsuani C, Siclari O, Camerini A, et al. Sorafenib in a patient with advanced hepatocellular carcinoma and serious impairment of left ventricular function: a case report. Cases J. 2009; 2: 9133

134）Wong H, Tang YF, Yao TJ, et al. The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC). Oncologist. 2011; 16(12): 1721-8

135）Mir O, Coriat R, Blanchet B, et al. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One. 2012; 7(5): e37563. Epub 2012 May 30

136）Lencioni R, Kudo M, Ye SL, et al. First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study. Int J Clin Pract. 2012; 66(7): 675-83

137）Teng CL, Hwang WL, Chen YJ, et al. Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver trans-plantation: a case control study. World J Surg Oncol. 2012; 10: 41

138）Vitale A, Volk ML, Pastorelli D, et al. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology. 2010; 51(1): 165-73

139）Yoon DH, Ryoo BY, Ryu MH, et al. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Jpn J Clin Oncol. 2010; 40(8): 768-73

140）Tan WF, Qiu ZQ, Yu Y, et al. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. Acta Pharmacol Sin. 2010; 31(12): 1643-8

141）Weinmann A, Niederle IM, Koch S, et al. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Dig Liver Dis. 2012; 44(5): 432-7

142）Worns MA, Schuchmann M, Duber C, et al. Sunitinib in patients with advanced hepato-cellular carcinoma after progression under sorafenib treatment. Oncology. 2010; 79(1-2): 85-92

143）Yau T, Wong H, Chan P, et al. Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. Invest New Drugs. 2012 Mar 9. [Epub ahead of print]

144）Poggi G, Montagna B, Melchiorre F, et al. Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma. Anticancer Res. 2011; 31(11): 3927-33

145）Mir O, Coriat R, Boudou-Rouquette P, et al. Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib. Med Oncol. 2012 Mar 17. [Epub ahead of print]

146）Yang Y, Lu Y, Wang C, et al. Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma. Cell Biochem Biophys. 2012; 63(2): 159-69

147）Zhao JD, Liu J, Ren ZG, et al. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study. Radiat Oncol. 2010; 5: 12

148）Dufour JF, Hoppe H, Heim MH, et al. Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study. Oncologist. 2010; 15(11): 1198-204

149）Cabrera R, Pannu DS, Caridi J, et al. The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma. Aliment Pharmacol Ther. 2011; 34(2): 205-13

150）Pawlik TM, Reyes DK, Cosgrove D, et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011; 29(30): 3960-7

151）Park JW, Koh YH, Kim HB, et al. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol. 2012; 56(6): 1336-42

152）Sansonno D, Lauletta G, Russi S, et al. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist. 2012; 17(3): 359-66

153）Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemo-embolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011; 47(14): 2117-27

154）Lee SJ, Lee J, Park SH, et al. Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. Invest New Drugs. 2012; 30(4): 1540-7

155）Williet N, Dubreuil O, Boussaha T, et al. Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma. World J Gastroenterol. 2011; 17(17): 2255-8

156）Hsu CH, Shen YC, Lin ZZ, Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol. 2010; 53(1): 126-31

157）Petrini I, Lencioni M, Ricasoli M, et al. Phase II trial of sorafenib in combination with 5-flu-orouracil infusion in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2012; 69(3): 773-80

158）Abou-Alfa GK, Johnson P, Knox JJ, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010; 304(19): 2154-60

159）Finn RS, Kang YK, Mulcahy M, Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carci-noma. Clin Cancer Res. 2012; 18(7): 2090-8.

160）Huynh H, Choo SP, Toh HC, et al. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation. Curr Cancer Drug Targets. 2011; 11(8): 944-53

161）Koeberle D, Montemurro M, Samaras P, et al. Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010; 15(3): 285-92

162）Faivre S, Raymond E, Boucher E, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol. 2009; 10(8): 794-800

163）Boige V, Malka D, Bourredjem A, et al. Efficacy, safety, and biomarkers of single-agent bevacizumab therapy in patients with advanced hepatocellular carcinoma. Oncologist. 2012 Jun 15. [Epub ahead of print]

164）Britten CD, Gomes AS, Wainberg ZA, et al. Transarterial chemoembolization plus or minus intravenous bevacizumab in the treatment of hepatocellular cancer: a pilot study. BMC Cancer. 2012; 12: 16

165）Ku GY, De Lima Lopes G Jr, Chang AY. Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: a case series. Asia Pac J Clin Oncol. 2011; 7(2): 174-9

166）Kemeny NE, Schwartz L, Gonen M, et al. Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexa-methasone: does the addition of systemic beva-cizumab improve results? Oncology. 2011; 80(3-4): 153-9

167）Chiorean EG, Ramasubbaiah R, Yu M, et al. Phase II trial of erlotinib and docetaxel in advanced and refractory hepatocellular and biliary cancers: Hoosier Oncology Group GI06-101. Oncologist. 2012; 17(1): 13. Epub 2011 Dec 30

168）Kanai F, Yoshida H, Tateishi R, et al. A phase I/II trial of the oral antiangiogenic agent TSU-68 in patients with advanced hepatocellular carci-noma. Cancer Chemother Pharmacol. 2011; 67(2): 315-24

169）Philip PA, Mahoney MR, Holen KD, et al. Phase 2 study of bevacizumab plus erlotinib in patients with advanced hepatocellular cancer. Cancer. 2012; 118(9): 2424-30

170）Govindarajan R, Siegel E, Makhoul I, et al. Bevacizumab and erlotinib in previously untreated inoperable and metastatic hepato-cellular carcinoma. Am J Clin Oncol. 2012 May 24. [Epub ahead of print]

171）Yau T, Wong H, Chan P, et al. Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease. Invest New Drugs. 2012 Mar 9. [Epub ahead of print]

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp